Young David 4

What Happened
David Young, President of Research & Development and a company director at Processa Pharmaceuticals (PCSA), reported an open-market purchase of 1,706 shares on 2026-04-30 at $2.69 per share, totaling $4,589. This was a direct purchase (transaction code P), i.e., the insider acquired common stock rather than exercising derivatives or receiving an award.

Key Details

• Transaction date and price: 2026-04-30 — 1,706 shares at $2.69 each.
• Total value: $4,589.
• Transaction type/code: Open-market purchase (P = Purchase).
• Shares owned after transaction: Not specified in the reported filing.
• Footnotes/notable plan: No 10b5-1 plan, tax withholding, or other footnotes disclosed in the filing.
• Filing timeliness: Form 4 filed on 2026-05-01 (timely relative to the 2026-04-30 transaction).

Context
This was a straightforward open-market buy rather than an option exercise or award. Insider purchases can be interpreted as a direct investment by management, but the small dollar amount here ($4.6K) is modest; avoid inferring strong company-wide sentiment solely from this single, low-value buy.